RESPIRE : breathing new life into bronchiectasis
RESPIRE, definable as “the recovery of hope, courage and strength after a time of difficulty”, is apt in the context of bronchiectasis therapy. Despite its recent renaissance, including the publication of the first international guidelines for the management of bronchiectasis, only a single treatmen...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Journal Article |
| Language: | English |
| Published: |
2019
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10356/85385 http://hdl.handle.net/10220/49222 |
| _version_ | 1811678186184900608 |
|---|---|
| author | Chalmers, James D. Chotirmall, Sanjay Haresh |
| author2 | Lee Kong Chian School of Medicine (LKCMedicine) |
| author_facet | Lee Kong Chian School of Medicine (LKCMedicine) Chalmers, James D. Chotirmall, Sanjay Haresh |
| author_sort | Chalmers, James D. |
| collection | NTU |
| description | RESPIRE, definable as “the recovery of hope, courage and strength after a time of difficulty”, is apt in the context of bronchiectasis therapy. Despite its recent renaissance, including the publication of the first international guidelines for the management of bronchiectasis, only a single treatment recommendation in the 2017 European Respiratory Society guidelines was supported by high-quality evidence [1]. This is a timely reminder of the real and challenging battle ahead, to deliver evidence-based appropriate and effective therapies to patients. In this issue of the European Respiratory Journal, a major “blow” in this battle has been struck and appears to have landed its intended target [2, 3]. The RESPIRE 1 and 2 trials evaluated 32.5 mg ciprofloxacin dry powder inhalation (DPI) administered twice daily versus placebo in two separate 2×2 arm trials. Taken together, these two trials represent the largest clinical trial programme ever conducted in bronchiectasis. Each trial studied a 14- and 28-day on/off drug regime over a 48-week period. The two trials differed by: 1) their enrolling countries; and 2) statistical handling of the data. RESPIRE 1 largely enrolled across Europe, North and South America, Australia and included Japan, while RESPIRE 2 focused on Asia and Eastern Europe. The inclusion criteria were the same for each set of trials, requiring patients with bronchiectasis infected with one of a list of the most commonly identified pathogens, and a history of ≥2 exacerbations in the previous year. |
| first_indexed | 2024-10-01T02:49:15Z |
| format | Journal Article |
| id | ntu-10356/85385 |
| institution | Nanyang Technological University |
| language | English |
| last_indexed | 2024-10-01T02:49:15Z |
| publishDate | 2019 |
| record_format | dspace |
| spelling | ntu-10356/853852020-03-07T12:57:23Z RESPIRE : breathing new life into bronchiectasis Chalmers, James D. Chotirmall, Sanjay Haresh Lee Kong Chian School of Medicine (LKCMedicine) Science::Medicine Bronchiectasis Breathing RESPIRE, definable as “the recovery of hope, courage and strength after a time of difficulty”, is apt in the context of bronchiectasis therapy. Despite its recent renaissance, including the publication of the first international guidelines for the management of bronchiectasis, only a single treatment recommendation in the 2017 European Respiratory Society guidelines was supported by high-quality evidence [1]. This is a timely reminder of the real and challenging battle ahead, to deliver evidence-based appropriate and effective therapies to patients. In this issue of the European Respiratory Journal, a major “blow” in this battle has been struck and appears to have landed its intended target [2, 3]. The RESPIRE 1 and 2 trials evaluated 32.5 mg ciprofloxacin dry powder inhalation (DPI) administered twice daily versus placebo in two separate 2×2 arm trials. Taken together, these two trials represent the largest clinical trial programme ever conducted in bronchiectasis. Each trial studied a 14- and 28-day on/off drug regime over a 48-week period. The two trials differed by: 1) their enrolling countries; and 2) statistical handling of the data. RESPIRE 1 largely enrolled across Europe, North and South America, Australia and included Japan, while RESPIRE 2 focused on Asia and Eastern Europe. The inclusion criteria were the same for each set of trials, requiring patients with bronchiectasis infected with one of a list of the most commonly identified pathogens, and a history of ≥2 exacerbations in the previous year. 2019-07-09T08:55:20Z 2019-12-06T16:02:51Z 2019-07-09T08:55:20Z 2019-12-06T16:02:51Z 2018 Journal Article Chotirmall, S. H., & Chalmers, J. D. (2018). RESPIRE : breathing new life into bronchiectasis. European Respiratory Journal, 51(1), 1702444-. doi:10.1183/13993003.02444-2017 0903-1936 https://hdl.handle.net/10356/85385 http://hdl.handle.net/10220/49222 10.1183/13993003.02444-2017 en European Respiratory Journal © 2018 ERS. All rights reserved. |
| spellingShingle | Science::Medicine Bronchiectasis Breathing Chalmers, James D. Chotirmall, Sanjay Haresh RESPIRE : breathing new life into bronchiectasis |
| title | RESPIRE : breathing new life into bronchiectasis |
| title_full | RESPIRE : breathing new life into bronchiectasis |
| title_fullStr | RESPIRE : breathing new life into bronchiectasis |
| title_full_unstemmed | RESPIRE : breathing new life into bronchiectasis |
| title_short | RESPIRE : breathing new life into bronchiectasis |
| title_sort | respire breathing new life into bronchiectasis |
| topic | Science::Medicine Bronchiectasis Breathing |
| url | https://hdl.handle.net/10356/85385 http://hdl.handle.net/10220/49222 |
| work_keys_str_mv | AT chalmersjamesd respirebreathingnewlifeintobronchiectasis AT chotirmallsanjayharesh respirebreathingnewlifeintobronchiectasis |